Cover Image
Market Research Report
Product code 
975208

Neurovascular Embolization Devices - Medical Devices Pipeline Assessment, 2020

Published: | GlobalData | 107 Pages | Delivery time: 1-2 business days

Price

Back to Top
Neurovascular Embolization Devices - Medical Devices Pipeline Assessment, 2020
Published: December 1, 2020
GlobalData
Content info: 107 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

GlobalData's Medical Devices sector report, "Neurovascular Embolization Devices - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Neurovascular Embolization Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Neurovascular Embolization Devices are used to treat abnormalities in blood vessels in the brain, namely, brain aneurysms and arteriovenous malformations (AVM). These devices occlude or prevent blood flow to unwanted vessel malformations.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Neurovascular Embolization Devices under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Neurovascular Embolization Devices and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to Buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Neurovascular Embolization Devices under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date
Product Code: GDME1063EPD

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Introduction

  • 2.1 Neurovascular Embolization Devices Overview

3 Products under Development

  • 3.1 Neurovascular Embolization Devices - Pipeline Products by Stage of Development
  • 3.2 Neurovascular Embolization Devices - Pipeline Products by Segment
  • 3.3 Neurovascular Embolization Devices - Pipeline Products by Territory
  • 3.4 Neurovascular Embolization Devices - Pipeline Products by Regulatory Path
  • 3.5 Neurovascular Embolization Devices - Pipeline Products by Estimated Approval Date
  • 3.6 Neurovascular Embolization Devices - Ongoing Clinical Trials

4 Neurovascular Embolization Devices - Pipeline Products under Development by Companies

  • 4.1 Neurovascular Embolization Devices Companies - Pipeline Products by Stage of Development
  • 4.2 Neurovascular Embolization Devices - Pipeline Products by Stage of Development

5 Neurovascular Embolization Devices Companies and Product Overview

  • 5.1 Ancure LLC Company Overview
    • 5.1.1 Ancure LLC Pipeline Products & Ongoing Clinical Trials Overview
  • 5.2 Aneuclose LLC Company Overview
    • 5.2.1 Aneuclose LLC Pipeline Products & Ongoing Clinical Trials Overview
  • 5.3 Artio Medical Company Overview
    • 5.3.1 Artio Medical Pipeline Products & Ongoing Clinical Trials Overview
  • 5.4 Avantec Vascular Corp Company Overview
    • 5.4.1 Avantec Vascular Corp Pipeline Products & Ongoing Clinical Trials Overview
  • 5.5 Balt USA LLC Company Overview
    • 5.5.1 Balt USA LLC Pipeline Products & Ongoing Clinical Trials Overview
  • 5.6 BioCure Inc Company Overview
    • 5.6.1 BioCure Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.7 Cerenovus Company Overview
    • 5.7.1 Cerenovus Pipeline Products & Ongoing Clinical Trials Overview
  • 5.8 Cerus Endovascular Ltd Company Overview
    • 5.8.1 Cerus Endovascular Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.9 Collagen Matrix Inc Company Overview
    • 5.9.1 Collagen Matrix Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.10 CranioVation Company Overview
    • 5.10.1 CranioVation Pipeline Products & Ongoing Clinical Trials Overview
  • 5.11 Dartmouth College Company Overview
    • 5.11.1 Dartmouth College Pipeline Products & Ongoing Clinical Trials Overview
  • 5.12 DePuy Synthes Inc Company Overview
    • 5.12.1 DePuy Synthes Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.13 Evasc Medical Systems Corp Company Overview
    • 5.13.1 Evasc Medical Systems Corp Pipeline Products & Ongoing Clinical Trials Overview
  • 5.14 Integra LifeSciences Holdings Corp Company Overview
  • 5.15 Mayo Clinic Company Overview
    • 5.15.1 Mayo Clinic Pipeline Products & Ongoing Clinical Trials Overview
  • 5.16 Medtronic Plc Company Overview
    • 5.16.1 Medtronic Plc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.17 MicroPort NeuroTech Shanghai Co Ltd Company Overview
    • 5.17.1 MicroPort NeuroTech Shanghai Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.18 MicroVention Inc Company Overview
    • 5.18.1 MicroVention Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.19 Monarch Biosciences Inc Company Overview
    • 5.19.1 Monarch Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.20 NEOS Surgery SL Company Overview
    • 5.20.1 NEOS Surgery SL Pipeline Products & Ongoing Clinical Trials Overview
  • 5.21 Neurosigma Inc Company Overview
    • 5.21.1 Neurosigma Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.22 Qvanteq AG Company Overview
    • 5.22.1 Qvanteq AG Pipeline Products & Ongoing Clinical Trials Overview
  • 5.23 RWTH Aachen University Company Overview
    • 5.23.1 RWTH Aachen University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.24 Shape Memory Therapeutics, Inc. Company Overview
    • 5.24.1 Shape Memory Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.25 Sree Chitra Tirunal Institute for Medical Sciences & Technology Company Overview
    • 5.25.1 Sree Chitra Tirunal Institute for Medical Sciences & Technology Pipeline Products & Ongoing Clinical Trials Overview
  • 5.26 Stryker Neurovascular Company Overview
    • 5.26.1 Stryker Neurovascular Pipeline Products & Ongoing Clinical Trials Overview
  • 5.27 Terumo Corp Company Overview
    • 5.27.1 Terumo Corp Pipeline Products & Ongoing Clinical Trials Overview
  • 5.28 Transverse Medical Inc Company Overview
    • 5.28.1 Transverse Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.29 University of California Los Angeles Company Overview
    • 5.29.1 University of California Los Angeles Pipeline Products & Ongoing Clinical Trials Overview
  • 5.30 University of Minnesota Company Overview
    • 5.30.1 University of Minnesota Pipeline Products & Ongoing Clinical Trials Overview
  • 5.31 University of Wisconsin Madison Company Overview
    • 5.31.1 University of Wisconsin Madison Pipeline Products & Ongoing Clinical Trials Overview
  • 5.32 Weill Cornell Medical College Company Overview
    • 5.32.1 Weill Cornell Medical College Pipeline Products & Ongoing Clinical Trials Overview

6 Neurovascular Embolization Devices- Recent Developments

  • 6.1 Jun 29, 2020: DePuy Synthes renews cooperation agreement with AO Foundation to continue advancement of surgical education
  • 6.2 Jun 15, 2020: MicroPort announces strategic investment and forms joint venture with Indian medical device company purple medical
  • 6.3 May 15, 2020: Microport orthopedics group brings in new strategic investors
  • 6.4 Apr 15, 2020: J&J lifts dividend but cuts 2020 guidance
  • 6.5 Apr 14, 2020: BioCardia announces litigation financing in the case captioned Boston Scientific
  • 6.6 Mar 02, 2020: Stryker announces new Investor Relations leader
  • 6.7 Feb 25, 2020: Stryker announces nomination of new Director, Lisa Skeete Tatum
  • 6.8 Feb 24, 2020: 2020 Catalyst award winner Medtronic hires Chief Inclusion and Diversity Officer
  • 6.9 Feb 24, 2020: Merit Medical reports earnings for fourth quarter and year ended December 31, 2019, gives FY 2020 Guidance
  • 6.10 Feb 24, 2020: 2020 Catalyst Award Winner Medtronic hires Chief Inclusion and Diversity Officer
  • 6.11 Feb 18, 2020: Cerus Endovascular gets CE Mark for Contour Neurovascular System
  • 6.12 Feb 18, 2020: Medtronic reports third quarter financial results 2020
  • 6.13 Feb 11, 2020: Metactive Medical Announces Name Change to Artio Medical
  • 6.14 Feb 05, 2020: Boston Scientific announces results for fourth quarter and full year 2019
  • 6.15 Feb 05, 2020: Stryker expands Flower Mound regional headquarters
  • 6.16 Jan 28, 2020: Stryker reports 2019 results and 2020 outlook
  • 6.17 Jan 27, 2020: Merit Medical issues statement regarding director nominations from starboard
  • 6.18 Jan 23, 2020: Johnson & Johnson announces $250 million commitment to support Frontline Health Workers, reaching 100 million people by 2030
  • 6.19 Jan 22, 2020: Johnson & Johnson reports 2019 fourth-quarter and full year results
  • 6.20 Jan 15, 2020: Merit milestones: facilities in Galway and Tijuana reach 1,000 employees
  • 6.21 Jan 14, 2020: Boston Scientific announces preliminary unaudited sales for the fourth quarter and full year 2019
  • 6.22 Jan 13, 2020: Healthpeak announces lease with Johnson & Johnson Subsidiary at The Shore at Sierra Point
  • 6.23 Jan 09, 2020: MicroVention announces FDA premarket approval of a new flow diverter for the treatment of brain aneurysms
  • 6.24 Jan 08, 2020: Terumo announces novel intrasaccular aneurysm treatment device receives approval in Japan
  • 6.25 Dec 25, 2019: GST profiteering: Rs 230-crore penalty on Johnson & Johnson
  • 6.26 Dec 05, 2019: Johnson & Johnson names Hubert Joly, Executive Chairman of Best Buy and Mark A. Weinberger, Former EY Global Chairman and CEO to its Board of Directors
  • 6.27 Dec 04, 2019: Lumeon and Medtronic partner to deliver new models of care in Europe

7 Appendix

  • 7.1 Methodology
  • 7.2 About GlobalData
  • 7.3 Contact Us
  • 7.4 Disclaimer

List of Tables

List of Tables

  • Table 1: Neurovascular Embolization Devices - Pipeline Products by Stage of Development
  • Table 2: Neurovascular Embolization Devices - Pipeline Products by Segment
  • Table 3: Neurovascular Embolization Devices - Pipeline Products by Territory
  • Table 4: Neurovascular Embolization Devices - Pipeline Products by Regulatory Path
  • Table 5: Neurovascular Embolization Devices - Pipeline Products by Estimated Approval Date
  • Table 6: Neurovascular Embolization Devices - Ongoing Clinical Trials
  • Table 7: Neurovascular Embolization Devices Companies - Pipeline Products by Stage of Development
  • Table 8: Neurovascular Embolization Devices - Pipeline Products by Stage of Development
  • Table 9: Ancure LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 10: Drug-Eluting Embolization Coil - Product Status
  • Table 11: Drug-Eluting Embolization Coil - Product Description
  • Table 12: Aneuclose LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 13: Janjua Aneurysm Net - Product Status
  • Table 14: Janjua Aneurysm Net - Product Description
  • Table 15: Artio Medical Pipeline Products & Ongoing Clinical Trials Overview
  • Table 16: Ballstent Microcatheter - Product Status
  • Table 17: Ballstent Microcatheter - Product Description
  • Table 18: Endura Embolization Coils - Product Status
  • Table 19: Endura Embolization Coils - Product Description
  • Table 20: Endura Embolization Device - Product Status
  • Table 21: Endura Embolization Device - Product Description
  • Table 22: Avantec Vascular Corp Pipeline Products & Ongoing Clinical Trials Overview
  • Table 23: Endovascular Embolization Device - Product Status
  • Table 24: Endovascular Embolization Device - Product Description
  • Table 25: Balt USA LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 26: SQUID Liquid Embolic Device - Product Status
  • Table 27: SQUID Liquid Embolic Device - Product Description
  • Table 28: Balt USA LLC - Ongoing Clinical Trials Overview
  • Table 29: SQUID Liquid Embolic Device - The Squid Trial for the Embolization of the Middle Meningeal Artery (STEM)
  • Table 30: BioCure Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 31: GelCoil - Product Status
  • Table 32: GelCoil - Product Description
  • Table 33: LiquiGel - Product Status
  • Table 34: LiquiGel - Product Description
  • Table 35: Cerenovus Pipeline Products & Ongoing Clinical Trials Overview
  • Table 36: BRAVO Flow Diverter - Product Status
  • Table 37: BRAVO Flow Diverter - Product Description
  • Table 38: EmboTrap Revascularization Device - Product Status
  • Table 39: EmboTrap Revascularization Device - Product Description
  • Table 40: Self-Expanding Stent - Product Status
  • Table 41: Self-Expanding Stent - Product Description
  • Table 42: Cerenovus - Ongoing Clinical Trials Overview
  • Table 43: EmboTrap Revascularization Device - A Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke: SELECT 2
  • Table 44: Cerus Endovascular Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 45: Contour Neurovascular System - Product Status
  • Table 46: Contour Neurovascular System - Product Description
  • Table 47: Neqstent Coil Assisted Flow Diverter Device - Product Status
  • Table 48: Neqstent Coil Assisted Flow Diverter Device - Product Description
  • Table 49: Cerus Endovascular Ltd - Ongoing Clinical Trials Overview
  • Table 50: Contour Neurovascular System - Contour Neurovascular System - European Pre-market Unruptured Aneurysm Study (CERUS)

List of Figures

List of Figures

  • Figure 1: Neurovascular Embolization Devices - Pipeline Products by Stage of Development
  • Figure 2: Neurovascular Embolization Devices - Pipeline Products by Segment
  • Figure 3: Neurovascular Embolization Devices - Pipeline Products by Territory
  • Figure 4: Neurovascular Embolization Devices - Pipeline Products by Regulatory Path
  • Figure 5: Neurovascular Embolization Devices - Pipeline Products by Estimated Approval Date
  • Figure 6: Neurovascular Embolization Devices - Ongoing Clinical Trials